Bliss GVS Pharma Ltd
Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.
- Market Cap ₹ 1,284 Cr.
- Current Price ₹ 122
- High / Low ₹ 186 / 92.2
- Stock P/E 15.8
- Book Value ₹ 97.2
- Dividend Yield 0.41 %
- ROCE 11.2 %
- ROE 7.91 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 7.25% over past five years.
- Company has a low return on equity of 9.47% over last 3 years.
- Dividend payout has been low at 7.34% of profits over last 3 years
- Company has high debtors of 241 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Part of BSE Healthcare BSE Allcap BSE SmallCap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
354 | 288 | 313 | 326 | 348 | 298 | 427 | 442 | 466 | 636 | 598 | 605 | 675 | |
253 | 222 | 227 | 230 | 247 | 209 | 331 | 342 | 374 | 527 | 508 | 498 | 572 | |
Operating Profit | 101 | 66 | 86 | 97 | 101 | 88 | 95 | 100 | 91 | 109 | 90 | 107 | 103 |
OPM % | 29% | 23% | 28% | 30% | 29% | 30% | 22% | 23% | 20% | 17% | 15% | 18% | 15% |
15 | 30 | 21 | 23 | 9 | 11 | 33 | 37 | 18 | 35 | 51 | -8 | -6 | |
Interest | 7 | 9 | 11 | 14 | 9 | 7 | 3 | 7 | 4 | 4 | 10 | 6 | 7 |
Depreciation | 4 | 4 | 5 | 6 | 6 | 6 | 6 | 9 | 14 | 14 | 15 | 24 | 26 |
Profit before tax | 105 | 82 | 91 | 100 | 95 | 87 | 120 | 122 | 91 | 126 | 116 | 70 | 65 |
Tax % | 46% | 34% | 34% | 35% | 38% | 34% | 38% | 24% | 26% | 27% | 26% | 28% | |
57 | 54 | 60 | 66 | 59 | 57 | 74 | 92 | 68 | 93 | 85 | 51 | 46 | |
EPS in Rs | 5.50 | 5.23 | 5.82 | 6.36 | 5.73 | 5.53 | 7.22 | 8.95 | 6.54 | 8.94 | 8.21 | 4.84 | 4.38 |
Dividend Payout % | 13% | 10% | 12% | 8% | 10% | 18% | 14% | 6% | 8% | 6% | 6% | 10% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 7% |
3 Years: | 9% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | 4% |
5 Years: | 0% |
3 Years: | 4% |
TTM: | 19% |
Stock Price CAGR | |
---|---|
10 Years: | 0% |
5 Years: | 4% |
3 Years: | 15% |
1 Year: | -1% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 10% |
3 Years: | 9% |
Last Year: | 8% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 |
Reserves | 248 | 305 | 358 | 422 | 481 | 531 | 593 | 673 | 745 | 841 | 927 | 978 | 1,014 |
76 | 86 | 90 | 81 | 75 | 94 | 72 | 93 | 92 | 90 | 81 | 78 | 73 | |
122 | 85 | 97 | 71 | 99 | 59 | 61 | 79 | 98 | 139 | 122 | 87 | 120 | |
Total Liabilities | 456 | 486 | 555 | 585 | 666 | 694 | 736 | 855 | 946 | 1,080 | 1,140 | 1,153 | 1,217 |
49 | 54 | 82 | 79 | 76 | 73 | 79 | 180 | 175 | 225 | 326 | 331 | 326 | |
CWIP | 1 | 4 | 0 | 2 | 2 | 0 | 43 | 0 | 2 | 22 | 3 | 8 | 24 |
Investments | 19 | 19 | 19 | 21 | 21 | 18 | 18 | 18 | 18 | 18 | 18 | 19 | 19 |
388 | 409 | 454 | 483 | 567 | 602 | 596 | 657 | 750 | 815 | 793 | 795 | 849 | |
Total Assets | 456 | 486 | 555 | 585 | 666 | 694 | 736 | 855 | 946 | 1,080 | 1,140 | 1,153 | 1,217 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-52 | 65 | 15 | 60 | 38 | 23 | 48 | 63 | 67 | 114 | 44 | 126 | |
-27 | -24 | -19 | -15 | -29 | 16 | -68 | -60 | -62 | -92 | -13 | -110 | |
52 | -3 | -31 | -35 | -15 | -22 | 9 | -6 | -12 | -13 | -26 | -21 | |
Net Cash Flow | -27 | 38 | -35 | 10 | -6 | 17 | -11 | -3 | -6 | 9 | 5 | -4 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 225 | 232 | 246 | 280 | 251 | 346 | 293 | 334 | 273 | 234 | 243 | 241 |
Inventory Days | 48 | 53 | 58 | 59 | 61 | 100 | 89 | 93 | 121 | 96 | 86 | 109 |
Days Payable | 181 | 147 | 130 | 94 | 139 | 88 | 50 | 86 | 96 | 89 | 88 | 66 |
Cash Conversion Cycle | 92 | 138 | 173 | 245 | 173 | 357 | 332 | 342 | 298 | 241 | 241 | 283 |
Working Capital Days | 143 | 163 | 216 | 263 | 400 | 553 | 367 | 401 | 367 | 294 | 323 | 313 |
ROCE % | 40% | 25% | 24% | 23% | 19% | 15% | 19% | 18% | 12% | 14% | 13% | 11% |
Documents
Announcements
-
Intimation Of Change In Contact Details Of MUFG Intime India Private Limited, Registrar And Share Transfer Agent Of The Company.
22 Apr - Change in RTA MUFG Intime's email and website contact details announced.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulation, 2015.
15 Apr - USFDA approval for Mesalamine Suppositories 1000 mg ANDA.
-
Pendency Of Litigation(S)/Dispute(S)
12 Apr - Court rules in favor of Bliss GVS in trademark case.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Apr - Certificate under Regulation 74(5) for Q1 2025.
-
Announcement under Regulation 30 (LODR)-Change in Management
27 Mar - Resignation of Mr. Vilas Patil, GM – HR.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:
The company manufactures, markets, and exports over 150 branded formulations across 60+ therapeutic segments, including anti-malarial, anti-fungal, anti-bacterial, antibiotic, anti-inflammatory, contraceptive, and anti-diabetic. It sells these formulations as suppositories, pessaries, capsules, tablets, and syrups. Its portfolio includes over 150 brands such as P-Alaxin, Lonart, Funbact, and Lofnac. [1] [2]